[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol; 2010 Jan;96(2):211-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
  • There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant.
  • For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%.
  • Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1047-51 [17353924.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • (PMID = 19562255.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-06; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA062421-06; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS511532; NLM/ PMC3786190
  •  go-up   go-down


2. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.
  • In extremely rare condition, meningioma may occur together with meningioangiomatosis, and only 19 cases have been described in English literature until now.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • He had no stigmata of neurofibromatosis type 2.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • Neoplastic cells in atypical meningioma area were immunoreactive to epithelial membrane antigen (EMA) with high MIB-1 index of up to 20%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • The patient had been followed-up for 11 months without adjuvant radiotherapy or chemotherapy.
  • Meningioangiomatosis-associated meningioma is more likely to occur in younger patients and histologically to mimic parenchymal invasion of brain.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


3. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • Definite pathology: benign meningioma (WHO I).
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Tyagi D, Sharma BS, Gupta SK, Kaul D, Vasishta RK, Khosla VK: Expression of Bcl2 proto-oncogene in primary tumors of the central nervous system. Neurol India; 2002 Sep;50(3):290-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was addressed to find out the expression of Bcl2 proto-oncogene in tumor tissues derived from 25 patients with primary central nervous system tumors.
  • Both benign and malignant tumors (confirmed by histopathological examination) expressed Bcl2 gene product.
  • However, no correlation was found between the histopathological types of tumor, glial fibrillary acidic protein positivity and degree of Bcl2 expression.
  • Based on this study, we propose that the overexpression of Bcl2 gene product found in primary CNS tumors may be an important molecular event which is known to make the various types of tumor resistant to chemotherapy or radiotherapy.
  • [MeSH-minor] Adenoma / metabolism. Adult. Child. Ependymoma / metabolism. Female. Glioblastoma / metabolism. Humans. Male. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Middle Aged. Neurilemmoma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12391455.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


5. Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y: [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene]. Gan To Kagaku Ryoho; 2007 Feb;34(2):265-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
  • We report a case with malignant meningioma in which new preliminary treatment trial was performed by chemotherapy using anti-cancer drugs selected on the basis of multidrug resistance gene mRNA expression, such as MDR1, MGMT, MRP1, MRP2, MXR1, and DNA topoisomerase II alpha, from RT-PCR assay.
  • A 43-year-old female had been operated for parasagittal anaplastic meningioma three times because of recurrences. partial removal of tumor was performed at the 3rd operation.
  • RT-PCR assay of this tissue revealed overexpression of MDR1, MRP1, MRP2 and MGMT mRNA, but no ABCG 2 expression was observed.
  • Preliminary individual adjuvant chemotherapy based on mRNA expression of drug-resistance gene is available for the treatment of recurrent malignant meningioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. DNA Modification Methylases. DNA Repair Enzymes. Drug Administration Schedule. Female. Humans. Hydroxyurea / administration & dosage. Membrane Transport Proteins / biosynthesis. Mitoxantrone / administration & dosage. Multidrug Resistance-Associated Proteins / biosynthesis. P-Glycoprotein / biosynthesis. P-Glycoprotein / genetics. RNA, Messenger / biosynthesis. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301541.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / multidrug resistance-associated protein 2; BZ114NVM5P / Mitoxantrone; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


6. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Patients requiring enzyme-inducing antiepileptic drugs were ineligible.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • Tissue was available only from a minority of patients, but in these specimens there was uniform distribution of PDGFR, the drug target.
  • For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


7. Aung L, Gorlick RG, Shi W, Thaler H, Shorter NA, Healey JH, Huvos AG, Meyers PA: Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer; 2002 Oct 15;95(8):1728-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience.
  • BACKGROUND: The authors investigated the incidence and relative risk of secondary malignant neoplasms in long-term survivors of osteosarcoma.
  • All study patients received chemotherapy and/or surgery on one of six different protocols (T4, 5, 7, 10, 12, and CCG-7921/POG-9351).
  • Chemotherapy was scheduled for up to 40 weeks with some variations in the actual treatment period and consisted of various combinations of the following agents: high-dose methotrexate, doxorubicin, bleomycin, cyclophosphamide, dactinomycin, vincristine, cisplatin, and ifosfamide.
  • RESULTS: Secondary malignant neoplasms (SMN) occurred in 14 of 509 patients.
  • Only one had pulmonary metastasis at diagnosis and subsequent multiple recurrences that required thoracotomies and further modification of the chemotherapy regimen.
  • The time interval from diagnosis of the primary osteosarcoma to the development of SMN was 1.3-13.1 years (median, 5.5; 95% confidence interval [CI], 3.6-9.6).
  • The most common SMN occurred in the central nervous system (n = 4): anaplastic glioma, meningioma, high-grade glioma, and maxillary astrocytoma.
  • Although additional follow-up is warranted, the successes of current treatment regimens consisting of intensive, high-dose chemotherapy in combination with topoisomerase II inhibitors outweigh the risks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology. Osteosarcoma / complications. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12365021.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium: A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol; 2010 Jan;12(1):87-94
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
  • The objective of this phase I study was to determine the maximal tolerated dose (MTD) of erlotinib in patients with recurrent malignant gliomas (MGs) or recurrent meningiomas on enzyme-inducing antiepileptic drugs (EIAEDs).
  • This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Anticancer Drugs. 2008 Feb;19(2):209-16 [18176118.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Jan;64(1):31-41 [18000659.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5349-54 [11454673.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1480-8; discussion 1488-9 [15157306.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31 [8052651.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):5079-86 [8895767.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):3-12 [9407626.001]
  • [Cites] Oncol Res. 1997;9(11-12):581-7 [9563005.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • (PMID = 20150371.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCRR NIH HHS / RR / RR003186-190379; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62426; United States / NCRR NIH HHS / RR / M01 RR003186-190379; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC2940559
  •  go-up   go-down


9. Soares D, Char G, Crandon I, Shaw H: Malignant meningioma with extension into the neck. West Indian Med J; 2000 Mar;49(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma with extension into the neck.
  • We report a case of malignant meningioma with extension into the neck of a 39-year-old male.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Meningeal Neoplasms / drug therapy. Meningioma / diagnosis
  • [MeSH-minor] Adult. Brain / pathology. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10786459.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAMAICA
  •  go-up   go-down


10. Ware ML, Larson DA, Sneed PK, Wara WW, McDermott MW: Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma. Neurosurgery; 2004 Jan;54(1):55-63; discussion 63-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma.
  • OBJECTIVE: Recurrent atypical and malignant meningiomas are difficult to treat successfully.
  • Chemotherapy to date has been unsuccessful, and radiosurgery is limited to smaller tumors.
  • The addition of brachytherapy at the time of operation is an option.
  • Here, we report the results of our series of patients with recurrent malignant meningioma treated with resection and brachytherapy with permanent low-dose (125)I.
  • METHODS: The charts of patients in our database with recurrent atypical and malignant meningiomas treated by surgical resection and permanent (125)I brachytherapy at the University of California, San Francisco, between 1988 and 2002 were selected for this study.
  • RESULTS: Seventeen patients had recurrent malignant meningioma, and four had recurrent atypical meningioma.
  • The median time to progression after brachytherapy was 11.6 months for patients with malignant meningioma and 10.4 months for the combined group.
  • There was a trend toward longer disease-free survival time in patients after gross total resection versus subtotal resection and in patients with tumors located at the convexity and parasagittally versus at the cranial base.
  • The median overall survival after diagnosis was 9.4 years for patients with atypical meningioma, 6.6 years for those with malignant meningioma, and 8.0 years for all patients combined.
  • Survival from the time of resection and implantation of (125)I was 1.6 years for patients with atypical meningioma, 2.4 years for patients with malignant meningioma, and 2.4 years for the combined group.
  • CONCLUSION: The options for patients with recurrent atypical or malignant meningiomas are limited.
  • Our results suggest that for tumors not suitable for radiosurgery, resection followed by permanent brachytherapy should be considered as a potential salvage treatment.
  • However, this approach results in a relatively high complication rate in these heavily treated patients and requires meticulous surgical technique and medical therapies to assist with wound healing after surgery.
  • [MeSH-major] Brachytherapy. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14683541.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg; 2002 Aug;97(2):341-6
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
  • In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas.
  • The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.
  • In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant.
  • Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery.
  • Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.
  • All patients were evaluable for response to therapy.
  • In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8-151 weeks), and two of these showed clinical improvement.
  • One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations.
  • In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks.
  • Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Progression. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / physiopathology. Meningioma / drug therapy. Meningioma / physiopathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / physiopathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Remission Induction. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186462.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


12. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747051.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSTB protein, human; 0 / Cystatin A; 0 / Cysteine Proteinase Inhibitors; 88844-95-5 / Cystatin B; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


13. Incarbone M, Ceresoli GL, Di Tommaso L, Cappuzzo F, Inzirillo F, Infante M, Alloisio M: Primary pulmonary meningioma: report of a case and review of the literature. Lung Cancer; 2008 Dec;62(3):401-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary meningioma: report of a case and review of the literature.
  • Primary pulmonary meningioma (PPM) is a rare disease and usually presents as a solitary pulmonary nodule (SPN).
  • These lesions are mostly benign, but malignant PPMs have been reported, and primary lung cancer or metastasis may be suspected on imaging.
  • Diagnostic work-up included radiological chest study and in 3 cases positron emission tomography (PET) showing increased uptake, highly suspicious for malignancy.
  • Histological assessment revealed benign PPMs in 23 cases (including all 3 cases with positive PET) and malignant PPMs in 2 cases.
  • No recurrence was observed in long-term follow-up of patients with benign PPMs, but the two malignant PPMs relapsed.
  • Indeed, 8 patients (32%) were overtreated with major thoracic surgical resection or with chemotherapy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography / methods. Radiopharmaceuticals. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486986.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG: Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol; 2005 Sep;74(2):157-65
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
  • PURPOSE: Treatment of recurrent and progressive meningiomas remains a challenge in clinical neurooncology.
  • This study was designed to evaluate the efficacy of the simultaneous application of 3d-conformal radiotherapy and chemotherapy with hydroxyurea (HU).
  • PATIENTS AND METHODS: Twenty-one patients with recurrent or progressive meningiomas (13 benign, 4 atypical and malignant, 4 with unproven histology) received treatment by fractionated 3d-conformal radiation (55.8-59.4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg.
  • Progression free survival rates 1 year and 2 years after the initiation of radio-chemotherapy were 84% and 77%, respectively.
  • At the time of analysis a total of 6/21 pts presented with progressive disease with a median time to progression of 59 weeks.
  • Documented radio- and chemotherapy associated toxicity was minimal; only one patient discontinued HU treatment due to gastrointestinal symptoms such as anorexia and weight loss.
  • CONCLUSION: Results obtained in this study indicate that treatment with HU and simultaneous radiotherapy is safe and effective with disease stabilization in the majority of patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningioma / drug therapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / radiotherapy. Middle Aged. Pilot Projects. Radiotherapy, Conformal. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):191-4 [8283255.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):269-75 [12510778.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1000-5 [12605979.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] Strahlenther Onkol. 1999 Feb;175(2):62-7 [10065140.001]
  • [Cites] Forum (Genova). 2003;13(1):76-89 [14732889.001]
  • [Cites] J Clin Neurosci. 2002 Mar;9(2):156-8 [11922703.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):75-9 [10219797.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):755-61 [2108937.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):321-7 [10030256.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):241-9 [15015792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):65-70 [11578730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • (PMID = 16193387.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 36
  •  go-up   go-down


15. Chamberlain MC, Blumenthal DT: Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother; 2004 Jul;4(4):641-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: diagnosis and treatment.
  • Meningiomas are extra-axial CNS tumors which have a female predominance and occur in middle-to-late adult life.
  • Most meningiomas (90%) are benign, 6% are atypical and a small proportion (2%) are malignant.
  • Most patients diagnosed with a meningioma undergo surgical resection to relieve neurological symptoms.
  • Advocates of stereotactic radiotherapy have suggested this therapy in lieu of surgery particularly in poor surgical risk patients, patients with meningiomas in eloquent or surgically inaccessible locations and in patients of advanced age.
  • When the meningioma is unresectable or all other treatments (e.g., surgery and radiotherapy) have failed, hormonal chemotherapy may be considered.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853583.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


16. Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A: Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol; 2004 Mar-Apr;67(1-2):221-6
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas.
  • METHODS: Twelve patients with regrowing non-malignant meningiomas, were enrolled for a protocol of 2 years with continuous chemotherapy with hydroxyurea, 20 mg/kg/day.
  • Response to treatment was evaluated both clinically and by diagnostic imaging using computed tomography (CT) and 201-Thallium single photon emission CT.
  • Nine patients showed progressive disease, at least by one imaging procedure, with a median time to progression of 13 months (range 4-24).
  • CONCLUSION: In this series hydroxyurea has not shown effectiveness in the treatment of non-resectable slow-growing meningiomas: neither for achieving response, nor for arresting disease progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Tomography, Emission-Computed, Single-Photon. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • (PMID = 15072471.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


17. Rockhill J, Mrugala M, Chamberlain MC: Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus; 2007;23(4):E1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: an overview of diagnosis and treatment.
  • Meningiomas are extraaxial central nervous system tumors most often discovered in middle to late adult life, and are more often seen in women.
  • Ninety percent of meningiomas are benign, 6% are atypical, and 2% are malignant.
  • Most patients in whom a meningioma is diagnosed undergo resection to relieve neurological symptoms.
  • Radiotherapy may be administered as either conventional external-beam radiation therapy or stereotactically by linear accelerator, Leksell Gamma Knife, or Cyberknife radiosurgery.
  • Advocates of stereo-tactic radiotherapy have suggested this therapy in lieu of surgery particularly in high-risk patients, those with meningiomas in eloquent or surgically inaccessible locations, and elderly patients.
  • When the meningioma is unresectable or all other treatments (surgery and radiotherapy) have failed, hormonal therapy or chemotherapy may be considered.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961033.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


18. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH: Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol; 2007 Aug;84(1):49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature.
  • Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors which occur almost exclusively in infants and young children.
  • We describe a case of an AT/RT of the spinal cord in an adult.
  • In consultation with senior pathologists at other institutions, the lesion was initially diagnosed as a rhabdoid meningioma.
  • Subsequently, immunohistochemical studies revealed the absence of INI1 gene expression in the malignant cells, supporting the diagnosis of AT/RT.
  • Despite aggressive surgical resection, adjuvant chemotherapy and radiation therapy, the patient succumbed to the disease two and a half years after her initial presentation.
  • To our knowledge, this is the first case of a spinal atypical teratoid/rhabdoid tumor in an adult fully documented with molecular, immunohistochemical, cytogenetic and autopsy findings.
  • [MeSH-minor] Adult. Cervical Vertebrae. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Monosomy / diagnosis. Monosomy / genetics. SMARCB1 Protein

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):665-70 [15769941.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4012-9 [15899790.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2661-74 [16537910.001]
  • [Cites] Neurochirurgie. 1999 Sep;45(3):237-42 [10567965.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Clin Neurosci. 2003 May;10 (3):325-8 [12763338.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50 [16301525.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • (PMID = 17377740.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down


19. Kantar M, Cetingül N, Kansoy S, Anacak Y, Demirtaş E, Erşahin Y, Mutluer S: Radiotherapy-induced secondary cranial neoplasms in children. Childs Nerv Syst; 2004 Jan;20(1):46-9
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Secondary malignant neoplasms (SMN) in CNS tumor survivors has become problem of increasing concern over the last 20 years.
  • These tumors usually occur in a different site from the primary brain tumor several years after treatment.
  • CASE REPORT: We report secondary cranial malignant neoplasms in three patients who were treated with irradiation and chemotherapy for their primary brain tumors.
  • The first case is a male survivor of an orbital rhabdomyosarcoma who developed a meningioma 8 years later.
  • The other two cases are female survivors of ependymomas who were irradiated at the age of 3 and developed secondary gliomas 8 and 17 years after therapy respectively.
  • CONCLUSION: Patients carry a risk of developing SMNs many years later since irradiation is still an important part of the treatment.
  • An SMN may have a benign course, as in meningioma, or be a dilemma for the patient, as in glioblastoma.
  • [MeSH-major] Meningioma / etiology. Radiotherapy / adverse effects. Rhabdomyosarcoma, Embryonal / etiology
  • [MeSH-minor] Adult. Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Child. Child, Preschool. Desmin / metabolism. Ependymoma / etiology. Female. Glial Fibrillary Acidic Protein / metabolism. Glioblastoma / etiology. Glioblastoma / metabolism. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Male. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2001 Sep;31(9):607-9 [11511997.001]
  • [Cites] J Neurosurg Sci. 1989 Jul-Sep;33(3):271-9 [2693630.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1506-8 [3545441.001]
  • [Cites] Med Pediatr Oncol Suppl. 1996;1:29-34 [8643045.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Sep;17(5):362-8 [11642493.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):28-31 [8315464.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • (PMID = 14714135.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / S100 Proteins
  •  go-up   go-down


20. Yin WH, Yu GY, Ma Y, Rao HL, Lin SX, Shao CK, Liang Q, Guo N, Chen GQ, Zhou W, Zhao T, Zhu MG: [Follicular dendritic cell sarcoma: a clinicopathologic analysis of ten cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):522-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The remaining 5 patients were alive and disease-free after surgical excision (+/- chemotherapy and radiotherapy).
  • CONCLUSIONS: FDCS is a rare low to intermediate-grade malignant tumor.
  • Most cases are associated with good prognosis after surgical treatment, with or without chemotherapy and radiotherapy.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / metabolism. Dendritic Cell Sarcoma, Interdigitating / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Meningioma / pathology. Middle Aged. Nasopharyngeal Neoplasms / pathology. Paraneoplastic Syndromes / complications. Pemphigus / complications. Receptors, Complement 3b / metabolism. Receptors, Complement 3d / metabolism. Receptors, IgE / metabolism. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055030.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Receptors, Complement 3b; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 0 / monoclonal antibody D2-40
  •  go-up   go-down


21. Jabbour SK, Zhang Z, Arnold D, Wharam MD: Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience. J Neurooncol; 2009 Jan;91(2):227-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience.
  • BACKGROUND: We reviewed the risk of second tumor (ST), both malignant and benign, in germinoma survivors followed at the Johns Hopkins Hospital (JHH).
  • METHODS: Between 1977 and 2002, 27 patients with intracranial germinoma were treated with radiation therapy (RT).
  • In the presence of competing events, a cumulative incidence function of ST was estimated using the minimal time interval from the date of diagnosis to the date of ST, date of death, or date of last follow-up.
  • RESULTS: Five patients (18%) developed a ST of which 4 (15%) were malignant.
  • One developed a benign falcine meningioma.
  • Current trials of chemotherapy and reduced RT dose and volume offer the prospect of a lower risk of treatment-induced ST.
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / radiotherapy. Child. Combined Modality Therapy. Female. Follow-Up Studies. Germinoma / radiotherapy. Humans. Incidence. Male. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1874-8 [2556586.001]
  • [Cites] Intern Med. 2000 Nov;39(11):920-4 [11065243.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):83-5 [15527112.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):410-3 [17475364.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):453-9 [16767718.001]
  • [Cites] Neuropediatrics. 2005 Apr;36(2):71-7 [15822019.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2833-9 [17602088.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):723-6 [10442196.001]
  • [Cites] Urol Oncol. 2001 Mar;6(2):49-52 [11166620.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):14-21 [2536126.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2741-2; author reply 2742 [17039496.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):511-8 [12738328.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):294-7 [17243137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1165-70 [15001260.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):771-2 [7962639.001]
  • [Cites] Ann Oncol. 2005 May;16(5):793-7 [15802277.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):126-34 [15895370.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):77-82 [16047364.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • (PMID = 18813873.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Muller PJ, Wilson BC: Photodynamic therapy of brain tumors--a work in progress. Lasers Surg Med; 2006 Jun;38(5):384-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of brain tumors--a work in progress.
  • BACKGROUND AND OBJECTIVES: PDT has been used in the treatment of malignant brain tumors.
  • This communication updates our series of unselected malignant gliomas treated with Photofrin-PDT.
  • STUDY DESIGN AND METHODS: We examined the records of 112 patients with malignant gliomas, metastatic brain tumors and meningiomas treated with Photofrin-PDT at St. Michael's Hospital, Toronto.
  • [MeSH-major] Brain Neoplasms / drug therapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma / drug therapy. Carcinoma / mortality. Carcinoma / secondary. Female. Glioma / drug therapy. Glioma / mortality. Humans. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / mortality. Meningioma / drug therapy. Meningioma / mortality. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788926.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA43892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


23. Braun B, Lange M, Oeckler R, Mueller MM: Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol; 2004 Jun;68(2):131-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hematopoietic growth factors granulocyte- and granulocyte-macrophage colony stimulating factor (G-CSF and GM-CSF) are nowadays widely used in routine cancer therapies as potent factors to control radiation and chemotherapy induced neutropenia, a side effect that frequently endangers the success of tumor therapies.
  • Therefore, we analyzed immunohistochemically the protein expression of G-CSF, GM-CSF and their respective receptors in 30 meningioma tissues of different malignancy and histopathological type.
  • Both factors and receptors were not expressed in the corresponding normal tissue.
  • In addition, a strong perivascular expression of G-CSF was associated with a highly vascularized tumor type.
  • Thus, expression of both G-CSF and GM-CSF is associated with the expression of proliferation vascularization, two markers of an increasingly malignant tumor phenotype, suggesting a contribution of both factors to tumor progression.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / metabolism. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / pathology. Meningioma / blood supply. Meningioma / pathology. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Division. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] Am J Hematol. 1995 Jul;49(3):207-15 [7541602.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):477-88 [7510132.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Oncogene. 1993 Feb;8(2):231-6 [8426734.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] Int J Cancer. 1992 Jul 30;51(6):873-7 [1353485.001]
  • [Cites] Arch Dermatol Res. 1995;287(3-4):231-6 [7598526.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6264-7 [2205378.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Eur J Cancer. 1995;31A(3):302-7 [7540401.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3438-43 [7542171.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9253-7 [3057504.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2471-508 [7964965.001]
  • [Cites] Clin Exp Metastasis. 1996 Sep;14(4):351-7 [8878409.001]
  • [Cites] Cell. 2000 Nov 22;103(5):745-55 [11114331.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2791-808 [1720034.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3139-44 [8319222.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1557-67 [10550313.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):780-9 [10597195.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Head Neck. 1997 Jul;19(4):351-6 [9213115.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4141-7 [9307305.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):155-62 [10619499.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2611-4 [9205065.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):794-800 [9485037.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):905-6; discussion 907 [7688363.001]
  • [Cites] Cytokines Cell Mol Ther. 1998 Jun;4(2):113-20 [9681250.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):949-62 [9060833.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):19-26 [12125963.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1724-31 [8400229.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1413-9 [1372187.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):383-7 [10985899.001]
  • [Cites] Hematol Pathol. 1992;6(3):105-24 [1429340.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):541-5 [8123485.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):803-8 [7540696.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1310-3 [7682568.001]
  • [Cites] J Clin Invest. 1991 Mar;87(3):986-95 [1705569.001]
  • [Cites] J Neurooncol. 1993 Sep;17(3):183-90 [8164055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):845-50 [7688362.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1146-53 [1659742.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):78-84 [9935235.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1065-74 [8133992.001]
  • (PMID = 15218949.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


24. Vedrine PO, Thariat J, Merrot O, Percodani J, Dufour X, Choussy O, Toussaint B, Dassonville O, Klossek JM, Santini J, Jankowski R: Primary cancer of the sphenoid sinus--a GETTEC study. Head Neck; 2009 Mar;31(3):388-97
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Charts were reviewed for patient-, tumor-, and treatment-related parameters.
  • Pathologic findings included adenoid cystic carcinoma, adenocarcinoma, lymphoma, squamous cell carcinoma, sarcoma, neuroendocrine carcinoma, melanoma, and malignant hemangiopericytoma.
  • Radiotherapy was performed in 18 patients and chemotherapy in 12.
  • Surgery was rarely complete because of advanced stages at presentation, but it yielded better outcomes than other treatments without surgery in non lymphoma-cases.
  • Surgery, including debulking surgery, may be preferred to combined modality treatments without surgery.
  • Highly conformal radiotherapy (adjuvant or definitive) should be encouraged and optimized with concurrent chemotherapy in advanced stages.
  • Aggressive multidisciplinary management including surgery, chemotherapy, and radiotherapy should be encouraged and adapted on histology and tumor extensions.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / therapy. Chemotherapy, Adjuvant. Cranial Nerve Diseases / complications. Diagnostic Imaging. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Meningioma / mortality. Meningioma / pathology. Meningioma / therapy. Middle Aged. Multivariate Analysis. Plasmacytoma / mortality. Plasmacytoma / pathology. Plasmacytoma / therapy. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972425.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


25. Nagai H, Yamasaki T, Yamamoto Y, Takada D, Miyazaki T, Sugimoto K, Matsumoto Y, Akiyama Y, Moritake K: [Evaluation of brain tumors by simultaneous dual isotope SPECT with 201Tl-chloride and 99mTc-MIBI]. No Shinkei Geka; 2004 Oct;32(10):1029-37
Hazardous Substances Data Bank. THALLOUS CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Single photon emission computed tomography (SPECT) is useful for detecting brain tumors.
  • We evaluated 20 cases, including 2 glioblastomas, 7 anaplastic astrocytomas, 2 oligodendrogliomas, 2 anaplastic ependymomas, 2 medulloblastomas, 2 meningiomas, 1 malignant meningioma, 1 pituitary adenoma, and 1 craniopharyngioma.
  • We discuss the difference in the mechanism of accumulation of two tracers and the significance of simultaneous dual SPECT using them for the differential diagnosis of pituitary tumors, regrowth of oligodendrogliomas, and multidrug resistance of chemotherapy.
  • [MeSH-minor] Adenoma / radionuclide imaging. Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pituitary Neoplasms / radionuclide imaging. Thallium. Tomography, Emission-Computed, Single-Photon / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529789.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes; 7791-12-0 / thallium chloride; 971Z4W1S09 / Technetium Tc 99m Sestamibi; AD84R52XLF / Thallium
  •  go-up   go-down


26. Riffaud L, Bernard M, Lesimple T, Morandi X: Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review. J Neurooncol; 2006 Jan;76(2):207-11
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review.
  • Radiation-induced neoplasms of the central nervous system generally present as meningioma or sarcoma.
  • Spinal cord glioma after radiation therapy is rare and half of the cases documented occurred after treatment of Hodgkin's disease.A 39-year-old male presented with a 1-month history of gradually worsening neck ache and paraparesis.
  • The patient had been treated for stage IB Hodgkin's disease 9 years previously with combined therapy: MOPP-ABV and a 40-Gray mediastinal radiotherapy from T1 to T10.
  • Magnetic resonance imaging disclosed an intramedullary lesion from C6 to T2 and histopathological examination from biopsy demonstrated a malignant glioma.
  • Despite chemotherapy and additional radiotherapy, the patient's neurological status worsened and he died 11 months after initial presentation.
  • We suggest a strategy aimed solely at obtaining a tissue diagnosis to differentiate myelitis from tumor, and, in the event of tumor, confirming the strong likelihood of a high histopathological grade.
  • The very limited survival associated with these tumors regardless of therapy advocates palliative therapies without attempting complete resection.
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Spinal Cord / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1976 Nov;38(5):1939-40 [991108.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):19-26 [14700605.001]
  • [Cites] Lancet. 1975 Apr 26;1(7913):947-9 [48122.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1974 Oct;37(10 ):1177-80 [4443812.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2051-5 [7370950.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):886-94 [2424587.001]
  • [Cites] Neurosurgery. 1986 Jun;18(6):721-4 [3736799.001]
  • [Cites] J Neurosurg. 2001 Oct;95(2 Suppl):232-5 [11599842.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:101-6 [7515642.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] N Engl J Med. 1972 Nov 30;287(22):1119-22 [5082192.001]
  • [Cites] Neurosurgery. 1991 Oct;29(4):606-8 [1658678.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] J Neurosurg. 1980 Jun;52(6):838-41 [7381543.001]
  • [Cites] Neuroradiology. 1990;32(4):331-3 [2234396.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):233-41 [6420598.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] Surg Neurol. 1976 Apr;5(4):215-9 [817405.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1024-32 [766952.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:117-28 [1450072.001]
  • [Cites] Med Pediatr Oncol. 1987;15(2):89-95 [3295502.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • (PMID = 16158216.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Teixeira MJ, Lepski G, Correia C, Aguiar PH: Interstitial irradiation for CNS lesions. Stereotact Funct Neurosurg; 2003;81(1-4):24-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we investigated the efficacy of brachytherapy in the treatment of 138 patients with intracranial neoplasms of the CNS.
  • Of the total number of patients, 50 presented with glioblastoma multiforme, 45 presented with low-grade glioma, 19 presented with anaplastic astrocytoma, 23 presented with metastases and 1 presented with meningioma.
  • During the execution of this study, seeds of 125I (10-20 mCi) were inserted into the lesions to aim the irradiation at a low dose of 60 Gy in the margin of benign lesions or 1 cm beyond the radiological border of malignant lesions, which were visualized on CT scan.
  • The results of this procedure were evaluated in terms of the survival rates, which were assessed by Kaplan-Meier curves.
  • Significant relationships were not observed between the volume and location of the lesions, the whole-brain radiotherapy and chemotherapy, and the survival time of the patients.
  • A low Karnofsky Index score and older age were associated with a short survival time.
  • In light of the above, it was concluded that interstitial irradiation is a safe and effective method of treatment for brain tumors.
  • [MeSH-minor] Adult. Age Distribution. Female. Humans. Male. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14742960.001).
  • [ISSN] 1011-6125
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Lyons MK, Vora SA: Brain tumors: current issues in diagnosis and management. Semin Neurol; 2007 Sep;27(4):312-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There has been significant progress made in the diagnosis and treatment of brain tumors over the past 15 years.
  • This has largely been due to significant advances in radiographic imaging capabilities that have allowed for much earlier detection of disease, both new and recurrent.
  • More recent advances in chemotherapy options and double and triple crossover clinical trials are beginning to have an impact in the treatment of malignant brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Glioma / diagnosis. Glioma / therapy. Humans. Magnetic Resonance Imaging / methods. Male. Meningioma / diagnosis. Meningioma / therapy. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701868.001).
  • [ISSN] 0271-8235
  • [Journal-full-title] Seminars in neurology
  • [ISO-abbreviation] Semin Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Knox MK, Ménard C, Mason WP: Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri. J Neurooncol; 2010 Oct;100(1):145-9
Genetic Alliance. consumer health - Gliomatosis Cerebri.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptomeningeal gliomatosis is a known, yet uncommon, complication of malignant gliomas.
  • For both entities, limited data exist to guide treatment and prognosis is poor.
  • After a period of surveillance, intraparenchymal lesions developed in association with widespread diffuse infiltration.
  • Initial treatment consisted of six cycles of temozolomide chemotherapy.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Neoplasms, Neuroepithelial / etiology
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Magnetic Resonance Imaging / methods. Spinal Cord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1998 Oct;50(4):356-62; discussion 362 [9817460.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):163-8 [10619500.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):533-40 [2797391.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):201-5 [16200347.001]
  • [Cites] Neurology. 1992 Jan;42(1):252-4 [1310353.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):324-29; discussion 330 [12535360.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):247-53 [12533659.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):209-16 [17031563.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):161-7 [9524095.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):354-6 [15277636.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):223-226 [11154809.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):275-83 [8360714.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):73-82 [19353837.001]
  • [Cites] Acta Neurol Scand. 1989 Feb;79(2):133-9 [2711819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] J Clin Neurosci. 2006 Feb;13(2):298-301 [16431108.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 20146082.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A: Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res; 2007 Jan 1;13(1):68-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
  • Tumor hypoxia is often associated with more malignant phenotypes, resistance to therapy, and poor survival.
  • CONCLUSIONS: Tumor hypoxia is an endogenous feature of meningiomas, and therapeutic regimens should include strategies to target the subpopulation of hypoxic as well as the normoxic cells within the tumor.
  • Further studies to define the contribution of hypoxia to meningioma pathophysiology are warranted.
  • [MeSH-major] Anoxia. Antigens, Neoplasm / biosynthesis. Carbonic Anhydrases / biosynthesis. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Antineoplastic Agents / pharmacology. Female. Humans. Immunohistochemistry. Male. Microcirculation. Middle Aged. Phenotype. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200340.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


31. Roser F, Nakamura M, Brandis A, Hans V, Vorkapic P, Samii M: Transition from meningeal melanocytoma to primary cerebral melanoma. Case report. J Neurosurg; 2004 Sep;101(3):528-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe the first case of an intracranial transition of a melanocytoma into a primary malignant melanoma within a short time.
  • The histological workup following subtotal tumor resection of the initial tumor had revealed the typical features of a fibrous melanocytic meningioma without increased proliferation.
  • Ten years after the patient had completed treatment for the melanocytic meningioma, control neuroimaging demonstrated growth of the residual tumor with compression of the brainstem.
  • At this time immunohistochemical examinations demonstrated melanocytic features (expression of vimentin, S100 protein, and melan A) of the lesion with focally increased proliferation (5% of Ki-67-positive cells) but no higher mitotic activity.
  • A neuropathological examination revealed epithelial and anaplastic changes and indicated that the MIB-1 indices were greater than 25%.
  • Pleomorphic changes and a focal high mitotic activity led to the diagnosis of a primary cerebral malignant melanoma.
  • Despite whole-brain and stereotactic radiation therapy as well as chemotherapy, the patient died 4 months after the last neuropathological diagnosis.
  • Although grossly resembling a meningioma, melanocytomas lack the former's histological and immunohistochemical features.
  • The biological behavior of a melanocytoma is variable and recurrence may happen after subtotal resection, but intracranial transition into a malignant melanoma has not been observed previously.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm, Residual / pathology. Nevus / pathology
  • [MeSH-minor] Adult. Brain Stem / pathology. Cell Division. Disease Progression. Fatal Outcome. Female. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Meninges / pathology. Neoplasm Invasiveness / pathology. Reoperation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352613.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Goldhoff P, Warrington NM, Limbrick DD Jr, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB: Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res; 2008 Dec 1;14(23):7717-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: As favorable outcomes from malignant brain tumors remain limited by poor survival and treatment-related toxicity, novel approaches to cure are essential.
  • Here, we investigate the role of PDE4 in brain tumors and examine the utility of PDE4 as a therapeutic target.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was used to evaluate the expression pattern of a subfamily of PDE4, PDE4A, in multiple brain tumor types.
  • To determine therapeutic potential of PDE4 inhibition, Rolipram, temozolomide, and radiation were tested alone and in combination on mice bearing intracranial U87 xenografts.
  • RESULTS: We found that PDE4A is expressed in medulloblastoma, glioblastoma, oligodendroglioma, ependymoma, and meningioma.
  • Moreover, when PDE4A1 was overexpressed in Daoy medulloblastoma and U87 glioblastoma cells, in vivo doubling times were significantly shorter for PDE4A1-overexpressing xenografts compared with controls.
  • In long-term survival and bioluminescence studies, Rolipram in combination with first-line therapy for malignant gliomas (temozolomide and conformal radiation therapy) enhanced the survival of mice bearing intracranial xenografts of U87 glioblastoma cells.
  • Bioluminescence imaging indicated that whereas temozolomide and radiation therapy arrested intracranial tumor growth, the addition of Rolipram to this regimen resulted in tumor regression.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11392-9 [16357147.001]
  • [Cites] Drug Discov Today. 2005 Nov 15;10(22):1503-19 [16257373.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1666-78 [16478988.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):733-54 [16759164.001]
  • [Cites] Biochem Soc Trans. 2006 Aug;34(Pt 4):504-9 [16856845.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3799-810 [16940352.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] Curr Top Dev Biol. 2006;75:225-59 [16984814.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):651-8 [17234775.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5248-57 [17545604.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Chem Res Toxicol. 2000 Oct;13(10):944-8 [11080038.001]
  • [Cites] Cell Signal. 2001 Dec;13(12):911-8 [11728831.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28298-309 [11994273.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):268-76 [12432276.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] J Neurosurg. 1977 Apr;46(4):477-83 [191576.001]
  • [Cites] J Neurooncol. 1983;1(1):61-7 [6086852.001]
  • [Cites] Pharmacopsychiatry. 1984 Nov;17(6):188-90 [6393150.001]
  • [Cites] Biochem J. 1993 Jun 15;292 ( Pt 3):677-86 [7686364.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3058-61 [8391385.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):673-81 [7772057.001]
  • [Cites] Eur J Cancer. 1995;31A(5):714-7 [7640043.001]
  • [Cites] Biochem J. 1995 Sep 15;310 ( Pt 3):965-74 [7575434.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):161-8 [9120546.001]
  • [Cites] Neurosci Lett. 1998 Mar 6;244(1):41-6 [9578140.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):693-703 [9677330.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4733-43 [9822544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] Cell Signal. 2005 Sep;17(9):1158-73 [15905070.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1523-31 [16034090.001]
  • [Cites] Arch Toxicol. 2006 Feb;80(2):88-97 [16167140.001]
  • [Cites] Nat Methods. 2005 Aug;2(8):607-14 [16094386.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33178-89 [16030021.001]
  • [CommentIn] Clin Cancer Res. 2009 May 1;15(9):3238; author reply 3238-9 [19406836.001]
  • (PMID = 19047098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NINDS NIH HHS / NS / P30 NS057105; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R21 CA108677; United States / NCI NIH HHS / CA / P50 CA94056; United States / NCI NIH HHS / CA / P50 CA094056-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phosphodiesterase Inhibitors; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; K676NL63N7 / Rolipram
  • [Other-IDs] NLM/ NIHMS82831; NLM/ PMC2615415
  •  go-up   go-down


33. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exenteration is indicated in patients with malignant neoplasms of orbital contents.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Rhabdomyosarcoma / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down






Advertisement